

# FY22 FULL-YEAR RESULTS

Establishing scalable platforms for sustainable long-term growth

24 August 2022

## **ACKNOWLEDGEMENT OF COUNTRY**



HMC Capital acknowledges the Traditional Custodians of country throughout Australia and celebrates their diverse culture and connections to land, sea and community. We pay our respect to their Elders past, present and emerging and extend that respect to all Aboriginal and Torres Strait Islander peoples



# Agenda

- Page 6FY22 RESULT HIGHLIGHTS
- Page 12FUNDS MANAGEMENT
- Page 17FINANCIAL RESULTS
- Page 22 OUTLOOK & GUIDANCE
- Page 24APPENDICES



David Di Pilla Group Managing Director & CEO



Will McMicking Group CFO



**Misha Mohl** Group Head of Strategy, Research & IR

### **HMC** Capital Overview

ASX-listed alternative asset manager led by experienced and aligned management team



#### Our mission is to match capital with high conviction alternative investment opportunities

Notes: 1. As at 30-Jun-22 pro forma for HMC Capital Partners Fund I establishment post-balance date in Aug-22. 2. As at 22-Aug-22. 3. CAGR calculated over period from IPO (11-Oct-19) to 30-Jun-22. AUM at IPO equal to freehold property portfolio at IPO of \$925m.

### HMC Capital Track Record

Execution capability has accelerated evolution to a capital light alternative asset manager



# FY22 RESULT HIGHLIGHTS

### FY22 Strategic Outcomes

Our results demonstrate platform scalability and investment discipline



#### Well positioned to maintain growth trajectory and grow AUM beyond \$10bn by 2024



### FY22 Result Highlights

Transformational year of record growth in assets under management and earnings

<b>\$5.8bn</b> EXTERNAL AUM <sup>1</sup> 1% growth vs Jun-21 HMC Capital Partners Fund I ~\$300m FIRST CLOSE First investment in Sigma Healthcare up ~22% <sup>3</sup> Established unlisted fund capability
\$4.6bn ROSS TRANSACTIONS <sup>2</sup> If deployment highlighted by the quisition of Aventus Aven
\$64.1m ANAGEMENT REVENUES wth demonstrates ability to scale enerate meaningful fee income ANAGEMENT REVENUES Second PO in Sep-21 Largest REIT IPO since 2014

Notes. 1. As at 30-Jun-22 for HDN and HCW. External AUM pro forma for HMC Capital Partners Fund I establishment post-balance date in Aug-22. 2. Includes acquisitions and disposals by the HMC Group settled in FY22. 3. As at 22-Aug-22 7

### FY22 Result Highlights

Our success in FY22 builds on the significant growth since listing in October 2019



HMC Capital has delivered outsized returns through the successful execution of our capital light strategy

## HMC Capital's Sustainability Framework

We are committed to sustainable practices that drive long term value creation and achieve a positive impact on the communities in which we operate



### HMC Capital's Sustainability Framework

Net-Zero Emission Roadmap - Scope 1 & 2 Emissions reduction roadmap



Full FY22 Sustainability progress report included in the Appendix

**HM**Capital

Health

Co.

Home

Co.

# FUNDS MANAGEMENT

12

### HMC Capital Funds Management Platform Today

Scalable growth platforms underpinned by permanent capital sources and powerful megatrends

	Home Co. Daily Needs REIT	Health Co.	Partners Fund I
Established	Nov-20	Sep-21	Aug-22
Sector focus	Daily needs retail property	Healthcare & wellness property	High conviction strategic stakes & private equity
Capital	ASX listed	ASX listed	Unlisted
Fund term	Open-ended	Open-ended	Open-ended
HMC co-investment (%)	14.1%	20.9%	\$150m commitment <sup>4</sup>
Gross asset value (\$bn)¹	\$4.9bn	\$0.7bn	~\$0.3bn
FY22 AUM growth (%) <sup>2</sup>	249%	16%	nm
Gearing (%) <sup>3</sup>	30.6%	Net cash	nm
Available liquidity (\$m) <sup>3</sup>	\$380m	\$413m	nm

Over time HMC Capital will seek a relatively balanced split of external AUM across its target alternative asset classes



### External assets under management increases to \$5.8bn 321% growth in external AUM underpinned by record deployment in FY22





### Active Portfolio and Capital Management

Our response to the rising interest rate environment and market volatility has **protected capital and preserved funding capacity** for attractive investment opportunities which may emerge

	Home Co. HomeCo Daily Needs REIT	Health Co. ♥ HealthCo Healthcare & Wellness REIT
Strong FY22 results	<ul> <li>Successful merger integration with Aventus</li> <li>Delivered FY22 FFO of 8.85cpu, up 30% on FY21</li> <li>Strong operational intensity driving portfolio performance: <ul> <li>&gt;99% rent collection</li> <li>&gt;99% occupancy</li> <li>+5.7% leasing spreads</li> </ul> </li> </ul>	<ul> <li>Exceeded upgraded FY22 FFO guidance and delivered FY22 DPU in line with PDS forecast</li> <li>Strong operational intensity driving portfolio performance:         <ul> <li>100% rent collection</li> <li>99% occupancy</li> </ul> </li> </ul>
Proactive capital management	<ul> <li>Disciplined approach to acquisitions in competitive environment</li> <li>Fortified balance sheet with the sale of Sunshine Coast Home for \$140m representing a 6% premium to Dec-21 book value</li> <li>Decreased gearing to 30.6% and increased hedging to 73.5%         <ul> <li>Dry powder of ~\$500m</li> </ul> </li> </ul>	<ul> <li>Disciplined approach to acquisitions in competitive environment</li> <li>Fortified balance sheet with pro forma Jun-22 net cash position <ul> <li>Dry powder of ~\$413m</li> </ul> </li> <li>Sale of St Mary's for 71% premium to Dec-21 book value</li> <li>Announced on-market unit buyback</li> </ul>
Compelling growth outlook & megatrends	<ul> <li>Progressing \$0.5bn development pipeline</li> <li>More compelling acquisition opportunities starting to emerge</li> <li>Shift to omnichannel retailing is increasing the strategic value of HDN's last mile logistics real estate</li> <li>Asset class is attracting greater interest from institutional capital which is driving down cap rates</li> </ul>	<ul> <li>Progressing \$0.5bn+ development pipeline</li> <li>Actively working with major healthcare operators to establish strategic property partnerships</li> <li>Exposed to favourable structural tailwinds supporting long-term demand for healthcare services and infrastructure</li> <li>Significant institutional demand for healthcare real estate</li> </ul>

HMC Capital's two managed REITs are well capitalised and positioned to take advantage of attractive opportunities

### **Growth Strategy**

### Well positioned to maintain growth trajectory and grow AUM beyond \$10bn by 2024

Listed REITs	<ul> <li>ASX-listed REITs providing high quality and growing income streams via exposure to attractive megatrends</li> <li>Strong commitment to market leading governance and manager alignment to support long-term cost of capital</li> <li>Strong balance sheets and liquidity to capitalise on &gt;\$1bn value enhancing development pipeline across both REITs</li> <li>Disciplined approach to acquisitions to capitalise on large addressable markets and fragmented ownership</li> </ul>	\$8bn+ AUM
Unlisted Real Estate	<ul> <li>Today announcing two new unlisted institutional funds / capital partnerships</li> <li>New fund opportunities         <ul> <li>~\$1bn last mile logistics value-add fund targeting undervalued assets with repositioning upside</li> <li>Capital partnering opportunity for HMC's interest in the Camden healthcare precinct<sup>1</sup></li> </ul> </li> </ul>	target by 2024
HMC Capital Partners	<ul> <li>Unlisted fund targeting high conviction strategic stakes and private equity investments</li> <li>Situational capital targeting asset rich companies with trapped value where we can influence positive change</li> <li>Targeting to grow total funds raised to over \$500m over the next 6 months and \$1.5bn over time with ability to leverage investments and co-invest with institutional wholesale capital</li> <li>Engaged domestic and offshore placement agents to support institutional capital partnering strategy</li> </ul>	\$1.5bn+ AUM target by 2024
Corporate activity	<ul> <li>M&amp;A opportunities which provide new scalable platforms in target alternative sectors</li> <li>Capital partnerships for value-add opportunities including large-scale take private transactions</li> </ul>	\$10bn+ AUM

#### We are currently tracking 6-12 months ahead of our previously stated AUM growth target of \$10bn by the end of 2024

# FY22 FINANCIAL RESULTS

### Earnings summary

### FY22 pre-tax FFO of \$91.0m or 31.0 cents per share

\$ million	FY21	FY22
Direct property earnings	40.9	11.1
Share of associate profit (FFO) <sup>1</sup>	6.1	22.8
Investment income	47.0	33.9
Funds management revenue	10.9	64.1
Corporate expenses	(10.5)	(21.1)
Property funds management expenses	(2.4)	(10.4)
Finance costs (net)	(7.8)	(3.7)
Trading profit on sale of property	-	28.0
Other income	0.4	0.1
FFO (pre-tax)	37.5	91.0
Income tax expense <sup>2</sup>	(1.7)	(2.0)
FFO	35.8	89.0
Weighted average shares outstanding (m)	273.2	293.3
Pre-tax FFO (cps)	13.7	31.0
FFO (cps)	13.1	30.3
DPS (cents)	12.0	12.0

#### INVESTMENT

- Direct property earnings decreased from FY21 following the sale of remaining investment properties throughout FY22
- Share of associate profit adjusted to recognise share of FFO in HDN and HCW REIT co-investments (statutory share of associate profit of \$71.1m higher driven by fair value gains)

#### **FUNDS MANAGEMENT**

+\$53.2m growth in funds management revenue supported by growth of HDN and establishment of HCW in September 2021 (refer overleaf)

#### **CORPORATE / OTHER**

- Corporate expenses increased to support growth in funds management activities and includes 100% repayment of Jobkeeper receipts
- Trading profits on completed property sales primarily driven by sales to 3<sup>rd</sup> parties and managed funds

#### Pre-tax FFO (cps)



■ Underlying FFO (pre-tax) ■ Trading profits on sale of property (pre-tax)

### Funds management

Strong growth in funds management income streams supported by HDN and part period contribution from HCW

\$ million	FY21	FY22
Base management fees	4.4	17.3
Acquisition / disposal fees	1.6	30.6
Investment management revenue	6.0	47.8
Property management fees	2.1	10.6
Leasing fees	0.9	2.4
Development management fees	1.8	3.3
Property management revenue	4.8	16.3
Total funds management revenue	10.9	64.1

- Funds management revenue grew to \$64.1m in FY22 driven predominantly by the full period impact of HDN and the establishment of HealthCo Healthcare & Wellness REIT in Sep-21
- Completion of the Aventus transaction in Mar-22 resulted in a \$22.3m acquisition fee paid which HMC elected to receive via HDN units as consideration

### **Balance sheet**

Transitioned to capital light funds management model following successful monetisation of remaining LFR properties on balance sheet

\$ million	30-Jun-21	30-Jun-22
Cash and cash equivalents	11.7	57.6
Investment property	188.1	-
Assets held for sale <sup>1</sup>	478.6	-
Investment in associate	263.9	608.7
Deferred tax asset	19.6	-
Other assets	20.5	246.7
Total assets	982.4	912.9
Borrowings	253.1	-
Other liabilities	18.3	66.9
Total liabilities	271.4	66.9
Net assets	711.0	846.0
Securities on issue (m)	290.1	299.6
Adjusted NTA per share <sup>2</sup>	\$2.38	\$2.31
Gearing <sup>3</sup>	25.3%	Net cash
Look-through gearing <sup>4</sup>	28.6%	18.6%

- Key movements during the period relate to the sale of properties to HDN, HCW and third parties. Key assets now reside in investment in associate and comprise co-investments in:
  - HomeCo Daily Needs REIT (14.1% interest)
  - Healthcare & Wellness REIT (20.9% interest)
  - Camden JV healthcare developments (25.0% 40.3% interests)
- Proceeds from property sales has reduced drawn debt to nil and increased Jun-22 cash balance to \$57.6m. This included the sale of the Knoxfield and Roxburgh Park properties to 3<sup>rd</sup> parties at a combined 38% premium to Dec-21 book value
- Other assets includes \$186.8m intangible assets recorded as part of the Aventus transaction and a \$14.4m equity derivative in Sigma Healthcare Limited acquired as a seed asset for HMC Capital Partners Fund I

Notes: 1. Assets held for sale as at 30 June 2021 included 7 LFR centres sold to HDN on 1 July 2021 at disposal price of \$266.4m less the value of the bonus unit issue at \$8.9m and 10 assets to be sold to HCW at fair value of \$221.1m. 2. Net tangible assets adjusted to exclude right of use assets, lease liabilities, provisions and deferred tax assets and liabilities. 3. Gearing is defined as Borrowings (excluding unamortised establishment costs) less cash and cash equivalents divided by total assets excluding cash and cash equivalents and deferred tax assets 4. Look-through gearing includes the proportionate consolidation of gross assets and liabilities of equity accounted investments.

### Capital management

Well positioned to support future funds management activities

\$ million	30-Jun-21	30-Jun-22
Bank debt facility		
Maturity	Oct-22	Nov-23
Limit	315.0	275.0
Drawn	254.8	-
Cash and undrawn debt		
Bank debt undrawn	60.3	275.0
Cash at bank	11.7	57.6
Total cash & undrawn debt	72.0	332.6
Key metrics		
Gearing <sup>1</sup>	25.3%	nm
% of debt hedged	68.7%	nm
Weighted avg. debt cost <sup>2</sup> (% p.a.)	2.5%	nm

- Jun-22 net cash position of \$57.6m with nil drawn debt driven by the sale of properties during FY22 resulting in total cash and undrawn debt of \$332.6m as at Jun-22
- Additional divestments in FY23 expected to include HMC's interest in Camden healthcare development (The George Hospital). HMC has agreed to sell the property to HCW at a 5% discount to independent valuation on completion. The property is currently under construction and on track to complete in early 2023.
- HMC has committed to investing \$150.0m into the HMC Capital Partners fund which will be funded from cash and debt facilities

# OUTLOOK AND GUIDANCE



### **Outlook and Guidance**

### Well positioned to maintain growth trajectory and grow AUM well beyond \$10bn by 2024

#### FY23 Guidance

- In FY22 HMC Capital delivered FFO of 31.0 cps pre-tax (+126%) which included material transactional income (including trading profits)
  - We believe this is repeatable as we continue to scale our existing platform and execute on transformational opportunities
  - The unpredictable nature of the timing of transactional income makes it challenging to provide an FY23 FFO forecast at this time
  - FY23 DPS guidance of 12.0 cents is in-line with FY22

#### FY23 Outlook

- HMC Capital is well positioned moving into FY23 with strong momentum and a more established and diversified platform
  - HMC Capital Partners expands our platform into new alternative sectors including private equity and gives us greater flexibility to deploy capital during times of market volatility and dislocation
  - Our two REITs have strong balance sheets to take advantage of compelling investment opportunities including their value enhancing development pipelines
  - Today we are announcing two new unlisted real estate fund strategies targeting daily needs and healthcare sectors<sup>1</sup>
- We are currently tracking 6-12 months ahead of our previously stated AUM growth target of \$10bn by the end of 2024 and we believe the current market environment is creating compelling and strategic opportunities which could accelerate our growth

## Appendix A HMC CAPITAL PARTNERS FUND I

### Fund Overview

Fund I will target public and private companies in Australia and New Zealand with real asset backing where there is potential to unlock 'trapped' value through a private equity style investment approach

## \$1.5bn Target fund size

### 15%+ Target return (net)<sup>1</sup>

**2-4%** Target distribution yield<sup>1,2</sup> \$150m Sponsor commitment

Fund overvie	w
Fund Strategy	<ul> <li>High conviction investment strategy targeting predominantly real asset investment opportunities in Australia and New Zealand across both private and public markets</li> </ul>
Target capital allocation	<ul> <li>High conviction strategic stakes: 75-100% invested capital</li> <li>Private equity: 0-20% invested capital</li> </ul>
Fund Term	Open ended
Management Fees	<ul> <li>Management: 1.0% of NAV</li> <li>Performance: 20% performance fee above 7% hurdle rate, subject to High Water Mark</li> </ul>
Gearing	<ul> <li>Minimal gearing at the Fund level given the Fund expects to source debt financing on specific or pooled investments of the Fund</li> </ul>
Platform availability	<ul> <li>Mason Stevens</li> <li>Netwealth</li> <li>Ausmaq</li> </ul>

#### Investment team



Victoria Hardie Managing Director HMC Capital Partners



Misha Mohl Group Head of Strategy, IR & Research



Jamie Sun Group Corporate Finance Manager



Gavin Mullett Managing Director HMC Capital Partners



Nicholas Harris Head of Funds Management



Jourdon Whitfield-Horesh Senior Associate



Will McMicking Group Chief Financial Officer



Priya Kumar Senior Legal Counsel



Vaughan Anderson Risk Management

Notes: Terms are indicative and subject to change

1. Target Return and Target Distribution Yield are net of base management fees and costs but before tax (if applicable) and performance fees. Target return is 15%+ net IRR per annum measured over a 3 to 5 year holding period. 24 This is only a target and may not be achieved. 2. Following 2-year deployment period from First Close.



### Our Approach

We intend to leverage our **proven investment track record and skills** to generate attractive risk adjusted returns which are non-correlated to equity markets over the long-term





### Why Alternatives?

Demand for alternatives is growing exponentially as investors seek **exposure to non-correlated assets providing inflation protected returns** 



## Seed Investment in Sigma Healthcare (ASX: SIG)

HMC Capital recently acquired a ~14% stake in SIG as the first seed asset for HMC Capital Partners and is **up ~22% on our purchase price** 

Investment overview	SIG branded pharmacies	
Company description		
Founded in 1912, Sigma Healthcare provides wholesale and distribution services to pharmacies, hospitals and aged care across Australia	Amcal+ (	Euardian
Investment rationale		
Real asset backed: HMC entry price close to NAV, underpinned by freehold property	C PharmaSave	
✓ Strategic infrastructure: distribution network is underutilised following major capex		WHOLELIFE PHARMACY & HEALTHFOODS
<ul> <li>Megatrends: Exposed to attractive long-term healthcare megatrends – including ageing demographics which increases demand for pharmaceuticals</li> </ul>	Discour Drug Sto	nt
<ul> <li>Barriers to entry: high barriers to entry for new entrants</li> </ul>		0169

#### Share price performance



Source: IRESS (22-Aug-22), Company filings and broker research.

Notes: 1. Based on FY22A company filings and HMC Capital estimates Category breakdown: (i) Prescription includes revenue from wholesale of PBS medicines and CSO subsidy; (ii) Over-the-counter includes revenue from the wholesale of non-prescription health & beauty products; (iii) Hospital includes revenue from distribution to hospital pharmacies including direct to pharmacy and imprest services; (iv) Other includes revenue from MPS medication management, 3rd party and 4th party logistics, medical products and protective equipment through MIA and other revenue. 2. 5-year average FY17-FY21A per company filings. EBOS excludes animal care.

## Appendix B SUPPLEMENTARY INFORMATION

### Additional financial information

#### Income statement

\$ million	FY21	FY22
Direct property income	62.0	15.1
Direct property expenses	(21.6)	(4.0)
Direct property earnings	40.5	11.1
Share of associate profit	8.9	71.1
Property investments	49.4	82.2
Management fee income	10.9	64.1
Property funds management expenses	(2.4)	(10.4)
Corporate expenses	(11.0)	(21.6)
Profit on sale of investment property	-	28.0
Other	0.4	0.1
Straightlining and rent-free amortisation	(3.5)	(0.6)
Interest income	0.1	0.3
Interest expense	(10.9)	(5.8)
Operating profit before tax	32.9	136.4
Income tax expense	(89.4)	(14.1)
Operating profit/(loss) after tax	(56.4)	122.4
Acquisition and transaction costs	(1.9)	(11.4)
Net fair value movements	(22.0)	0.7
Gain on investment in associate	-	16.9
Impairment expenses	-	(21.3)
Discontinued operations	9.9	-
Loss on demerger	(15.4)	-
Statutory profit/(loss) after tax	(85.9)	107.3

#### FFO reconciliation to operating profit/(loss) after tax

\$ million	FY21	FY22
Operating profit/(loss) after tax	(56.4)	122.4
Deferred income tax expense	87.7	12.1
Straight-lining of rental income	3.5	0.6
Amortisation of borrowing costs	3.0	1.8
Share of associates profit	(2.8)	(48.3)
Depreciation	-	0.5
Other	0.9	-
FFO	35.8	89.0
Weighted average securities outstanding (m)	273.2	293.3
FFO per share	13.1	30.3

### Gross transactions and equity flows

#### FY22 Gross transactions<sup>1</sup>

	Daily Needs Retail	Healthcare & Wellness	HMC Balance Sheet	Total
Acquisitions (\$bn)	\$2.8bn	\$0.6bn	\$0.2bn	\$3.6bn
Disposals (\$bn)	-	-	\$1.0bn	\$1.0bn
Net transactions (\$bn)	\$2.8bn	\$0.6bn	(\$0.8bn)	\$2.6bn
Gross transactions (\$bn)	\$2.8bn	\$0.6bn	\$1.2bn	\$4.6bn

#### Equity flows

	FY21	FY22	FY22 proforma <sup>2</sup>
Listed (\$m)	\$0.9bn	\$2.9bn	\$2.9bn
Unlisted (\$m)	-	-	\$0.3bn
Gross equity inflows (\$m)	\$0.9bn	\$2.9bn	\$3.2bn
Net equity inflows (\$m)	\$0.9bn	\$2.9bn	\$3.2bn

Notes: 1. Includes settled and contracted acquisitions and disposals by the HMC Group. 2. Pro forma for post-balance date launch of HMC Capital Partners Fund I.

## **Distribution Strategy**

Our distribution strategy is designed to match diverse capital sources with high conviction alternative investment opportunities



## Sustainability Progress at HMC Capital

### Progressively implementing HMC Capital's Sustainability Commitments

Environment	Climate Action	<ul> <li>Progressing toward Net Zero by 2028. Progressively implementing the Smart Energy Management Strategy (EMS) across assets, 8 asset installations complete, with the balance of controlled assets to be complete by FY24</li> <li>18 NABERS certifications complete, with the balance of controlled assets to have NABERS ratings complete by calendar year end</li> <li>Green Star Performance rating commissioned for all controlled asset for completion by end of calendar year</li> <li>Robust Data Management system (ENVIZI) implemented, and operational</li> <li>Scope1 and Scope 2 Emission data will be published in the Sustainability report</li> <li>Solar PV roll-out to commence in the FY23 year, following the systematic EMS roll-out on assets</li> <li>All new Development projects incorporate sustainability initiatives</li> <li>Major development assets commissioned in past years and under construction, are being reviewed for 3rd party sustainability ratings</li> </ul>
	Green Future	<ul> <li>All acquisitions are assessed against a sustainability due diligence audit, informing investment decisions regarding sustainability credentials</li> <li>Progressing building certification ratings across new developments and major refurbishments</li> <li>Establishing sustainable design principles in future developments</li> <li>Undertaking a waste reduction and recovery strategy across assets</li> </ul>
Social	Connection	<ul> <li>HMC Capital has progressed the establishment of its charitable Foundation (a stand-alone public ancillary fund), and appointed an external Trustee and is proceeding to register the Foundation</li> <li>Needs assessments are carried out for new acquisitions as they relate to community needs</li> <li>HMC Capital is ensuring it responds to essential community needs as they relate to health, wellness and daily needs</li> <li>In this regard HMC Capital has assessed the common needs across its communities and will focus on supporting youth under 18. We are currently scoping partners to support this initiative across our assets</li> </ul>

## Sustainability Progress at HMC Capital

### Progressively implementing HMC Capital's Sustainability Commitments

Social	Respect	<ul> <li>HMC Capital respects the inherent dignity, safety, diversity and human rights of all stakeholders</li> <li>HMC Capital has joined the UN Global Compact</li> <li>In our asset management and property management areas, we work with our partners to promote responsible business practices in the community</li> <li>Regarding our diversity and inclusion FY25 target of 50% gender representation across our workforce, our target has been achieved increasing from FY21 of 43% to 51% in FY22</li> <li>We focus on the Health and Safety of our workforce, as well as providing safe, clean spaces for our tenants, customers and community in our assets</li> </ul>
		<ul> <li>Socialising and engaging our workforce on our sustainability commitments progresses</li> </ul>
Governance	Accountability	<ul> <li>Clear independence in decision making (Related Party Protocol and Policy)</li> <li>Transparent sustainability communication and reporting:         <ul> <li>Established Sustainability Committee in FY21</li> <li>Separate stand-alone Sustainability reporting</li> <li>Benchmark asset performance reporting in progress (NABERS, and Green Star Performance)</li> <li>Completed GRESB rating submission in 2022</li> </ul> </li> <li>Committed to report in accordance with the TCFD</li> <li>Modern Slavery report for HDN</li> </ul>
Gove	Alignment	<ul> <li>Corporate Governance Statement demonstrating commitment to ASX recommendations</li> <li>Clear and transparent governance <u>Investor Centre - HMC Capital</u></li> <li>HMC Capital Partners Fund I: <ul> <li>Diverse and gender balance Board achieved</li> <li>Comprehensive governance</li> </ul> </li> <li>Transparent remuneration report</li> <li>ESG KPIs established for leadership team and all employees</li> </ul>

### **Further Information**

#### Investors and analysts

**Misha Mohl** Group Head of Strategy, Research & IR HMC Capital

+61 422 371 575 misha.mohl@hmccapital.com.au Will McMicking Group Chief Financial Officer HMC Capital

+61 451 634 991 william.mcmicking@hmccapital.com.au



+61 411 361 361

john@brightoncomms.com.au



Media

### Disclaimer

This presentation (Presentation) has been prepared by Home Consortium Limited (ACN 138 990 593) ("HMC Capital")

#### Summary information

This Presentation contains summary information about the current activities of HMC Capital and its subsidiaries as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete. This Presentation does not purport to contain all the information that an investor should consider when making an investment decision nor does it contain all the information which would be required in a product disclosure statement or prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). This Presentation is subject to change without notice and HMC Capital may in its absolute discretion, but without being under any obligation to do so, update or supplement the information in this Presentation. Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. HMC Capital nor its respective representatives have independently verified any such market or industry data provided by third parties or industry or general publications. The information in this presentation should be read in conjunction with HMC Capital's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au. To the maximum extent permitted by law, HMC Capital and its respective subsidiaries, affiliates, related bodies, directors, corporates, officers, employees, partners, agents and advisers make no representation or warranty (express or implied) as to the currency, accuracy, reliability, reasonableness or completeness of the information in this Presentation and disclaim all responsibility and liability for the information (including without limitation, liability for negligence).

#### **Past Performance**

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance or reasonableness of any forward looking statements, forecast financial information or other forecast. Actual results could differ materially from those referred to in the Presentation.

#### Forward Looking Statements

This Presentation contains certain "forward looking statements". Forward looking statements can generally be identified by the use of forward looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" "outlook", "guidance", "continue" and other similar expressions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of HMC Capital. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of HMC Capital, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. HMC Capital, nor any other person, gives any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this presentation will actually occur. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. The forward looking statements are based on information available to HMC Capital as at the date of this Presentation. To the maximum extent permitted by law, HMC Capital and its directors, officers, partners, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions. Except as required by law or regulation (including the ASX Listing Rules), the Responsible Entity undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance